The Not-so-simple HDL Story: Is It Time to Revise the HDL Cholesterol Hypothesis?

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2012 Sep 11

PMID 22961164

Citations 156

Authors

Daniel J Rader

Alan R Tall

Affiliations

Soon will be listed here.

Citing Articles

Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews.

Xu Z, Yang S, Cui L BMC Nephrol. 2024; 25(1):400.

PMID: 39511510 PMC: 11542271. DOI: 10.1186/s12882-024-03808-3.

Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study.

Liu J, Oorloff M, Nadella A, Guo P, Ye M, Wang X Lipids Health Dis. 2024; 23(1):324.

PMID: 39354522 PMC: 11443751. DOI: 10.1186/s12944-024-02309-4.

A comprehensive analysis of the role of native and modified HDL in ER stress in primary macrophages.

Bobek J, Stuttgen G, Sahoo D Front Cardiovasc Med. 2024; 11:1448607.

PMID: 39328237 PMC: 11424405. DOI: 10.3389/fcvm.2024.1448607.

Gene transfer and genome editing for familial hypercholesterolemia.

Canepari C, Cantore A Front Mol Med. 2024; 3:1140997.

PMID: 39086674 PMC: 11285693. DOI: 10.3389/fmmed.2023.1140997.

High-Density Lipoprotein Particle Concentration and Size Predict Incident Coronary Artery Disease Events in a Cohort With Type 1 Diabetes.

Costacou T, Vaisar T, Miller R, Davidson W, Heinecke J, Orchard T J Am Heart Assoc. 2024; 13(14):e034763.

PMID: 38958152 PMC: 11292758. DOI: 10.1161/JAHA.123.034763.

References

Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3):299-308. DOI: 10.1001/jama.298.3.299. View

Khera A, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke M, Jafri K . Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364(2):127-35. PMC: 3030449. DOI: 10.1056/NEJMoa1001689. View

Murphy A, Westerterp M, Yvan-Charvet L, Tall A . Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta. 2011; 1821(3):513-21. PMC: 3234332. DOI: 10.1016/j.bbalip.2011.08.003. View

Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

Wang X, Collins H, Ranalletta M, Fuki I, Billheimer J, Rothblat G . Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117(8):2216-24. PMC: 1924499. DOI: 10.1172/JCI32057. View

Zhang Y, Zanotti I, Reilly M, Glick J, Rothblat G, Rader D . Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003; 108(6):661-3. DOI: 10.1161/01.CIR.0000086981.09834.E0. View

Schwartz G, Olsson A, Ballantyne C, Barter P, Holme I, Kallend D . Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009; 158(6):896-901.e3. DOI: 10.1016/j.ahj.2009.09.017. View

Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T . Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010; 30(7):1430-8. PMC: 2917780. DOI: 10.1161/ATVBAHA.110.207142. View

Yvan-Charvet L, Pagler T, Gautier E, Avagyan S, Siry R, Han S . ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010; 328(5986):1689-93. PMC: 3032591. DOI: 10.1126/science.1189731. View

10.

Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R . Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007; 117(12):3900-8. PMC: 2066200. DOI: 10.1172/JCI33372. View

11.

Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins C . Myocardial infarction accelerates atherosclerosis. Nature. 2012; 487(7407):325-9. PMC: 3401326. DOI: 10.1038/nature11260. View

12.

Rader D, Alexander E, Weibel G, Billheimer J, Rothblat G . The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2008; 50 Suppl:S189-94. PMC: 2674717. DOI: 10.1194/jlr.R800088-JLR200. View

13.

Westerterp M, Gourion-Arsiquaud S, Murphy A, Shih A, Cremers S, Levine R . Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 2012; 11(2):195-206. PMC: 3413200. DOI: 10.1016/j.stem.2012.04.024. View

14.

Steinberg D . Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006; 47(7):1339-51. DOI: 10.1194/jlr.R600009-JLR200. View

15.

Voight B, Peloso G, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen M . Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380(9841):572-80. PMC: 3419820. DOI: 10.1016/S0140-6736(12)60312-2. View

16.

Rayner K, Sheedy F, Esau C, Hussain F, Temel R, Parathath S . Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011; 121(7):2921-31. PMC: 3223840. DOI: 10.1172/JCI57275. View

17.

Nissen S, Tsunoda T, Tuzcu E, Schoenhagen P, Cooper C, Yasin M . Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290(17):2292-300. DOI: 10.1001/jama.290.17.2292. View

18.

Naik S, Wang X, da Silva J, Jaye M, Macphee C, Reilly M . Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2005; 113(1):90-7. DOI: 10.1161/CIRCULATIONAHA.105.560177. View